- Home
- IGMS vs UWMC Comparison
IGMS vs UWMC Comparison
Compare IGMS & UWMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- UWMC
- Stock Information
- Founded
- IGMS 1993
- UWMC 1986
- Country
- IGMS United States
- UWMC United States
- Employees
- IGMS N/A
- UWMC N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- UWMC Finance: Consumer Services
- Sector
- IGMS Health Care
- UWMC Finance
- Exchange
- IGMS Nasdaq
- UWMC Nasdaq
- Market Cap
- IGMS 962.1M
- UWMC 949.1M
- IPO Year
- IGMS 2019
- UWMC N/A
- Fundamental
- Price
- IGMS $9.47
- UWMC $5.84
- Analyst Decision
- IGMS Hold
- UWMC Hold
- Analyst Count
- IGMS 8
- UWMC 7
- Target Price
- IGMS $14.63
- UWMC $7.68
- AVG Volume (30 Days)
- IGMS 238.9K
- UWMC 3.4M
- Earning Date
- IGMS 11-08-2024
- UWMC 11-07-2024
- Dividend Yield
- IGMS N/A
- UWMC 6.86%
- EPS Growth
- IGMS N/A
- UWMC N/A
- EPS
- IGMS N/A
- UWMC N/A
- Revenue
- IGMS $2,918,000.00
- UWMC $2,727,467,000.00
- Revenue This Year
- IGMS $298.54
- UWMC $5.43
- Revenue Next Year
- IGMS N/A
- UWMC $24.97
- P/E Ratio
- IGMS N/A
- UWMC N/A
- Revenue Growth
- IGMS 57.64
- UWMC 29.95
- 52 Week Low
- IGMS $4.72
- UWMC $5.42
- 52 Week High
- IGMS $22.50
- UWMC $9.74
- Technical
- Relative Strength Index (RSI)
- IGMS 28.30
- UWMC 26.98
- Support Level
- IGMS $10.91
- UWMC $5.70
- Resistance Level
- IGMS $16.32
- UWMC $6.26
- Average True Range (ATR)
- IGMS 1.53
- UWMC 0.26
- MACD
- IGMS -0.79
- UWMC -0.01
- Stochastic Oscillator
- IGMS 0.80
- UWMC 13.73
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale and servicing of residential mortgage loans. The company provides independent mortgage advisors across the states and the district of Columbia.